Plain-English translation of NCT07667400 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
United States
Phase
Safety & dosing / Early efficacy
Sponsor
National Cancer Institute (NCI)
Enrollment target
~120 participants
Started
September 2026
Primary completion
October 2036
Age range
18 Years – 120 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michele L Reed, R.N.
National Cancer Institute (NCI)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.